Sangamo Therapeutics Inc (SGMO) concluded trading on Thursday at a closing price of $0.86, with 3.22 million shares of worth about $2.77 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 41.76% during that period and on September 25, 2024 the price saw a loss of about -7.64%. Currently the company’s common shares owned by public are about 208.22M shares, out of which, 198.84M shares are available for trading.
Stock saw a price change of 2.19% in past 5 days and over the past one month there was a price change of 5.41%. Year-to-date (YTD), SGMO shares are showing a performance of 57.45% which increased to 23.38% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.29 but also hit the highest price of $1.48 during that period. The average intraday trading volume for Sangamo Therapeutics Inc shares is 14.52 million. The stock is currently trading 1.73% above its 20-day simple moving average (SMA20), while that difference is up 7.55% for SMA50 and it goes to 32.67% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Sangamo Therapeutics Inc (NASDAQ: SGMO) currently have 208.22M outstanding shares and institutions hold larger chunk of about 41.89% of that.
The stock has a current market capitalization of $178.11M and its 3Y-monthly beta is at 1.23. It has posted earnings per share of -$1.38 in the same period. It has Quick Ratio of 1.03 while making debt-to-equity ratio of 1.23. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SGMO, volatility over the week remained 10.80% while standing at 10.16% over the month.
Stock’s fiscal year EPS is expected to rise by 68.83% while it is estimated to increase by 50.55% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by RBC Capital Mkts on November 03, 2023 offering a Sector perform rating for the stock and assigned a target price range of between $6 and $2 to it. Coverage by BofA Securities stated Sangamo Therapeutics Inc (SGMO) stock as an Underperform in their note to investors on April 28, 2023, suggesting a price target of $1.50 for the stock. On February 27, 2023, Wedbush Upgrade their recommendations, while on January 06, 2023, BofA Securities Downgrade their ratings for the stock with a price target of $5. Stock get a Neutral rating from Wedbush on June 13, 2022.
